128 related articles for article (PubMed ID: 3410358)
21. The significance of müllerian inclusions found at second-look laparotomy in patients with epithelial ovarian neoplasms.
Copeland LJ; Silva EG; Gershenson DM; Sneige N; Atkinson EN; Wharton JT
Obstet Gynecol; 1988 May; 71(5):763-70. PubMed ID: 2833713
[TBL] [Abstract][Full Text] [Related]
22. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration.
Lippman SM; Alberts DS; Slymen DJ; Weiner S; Aristizabal SA; Luditch A; Davis JR; Surwit EA
Cancer; 1988 Jun; 61(12):2571-7. PubMed ID: 3365677
[TBL] [Abstract][Full Text] [Related]
23. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.
Rubin SC; Randall TC; Armstrong KA; Chi DS; Hoskins WJ
Obstet Gynecol; 1999 Jan; 93(1):21-4. PubMed ID: 9916949
[TBL] [Abstract][Full Text] [Related]
24. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.
Hoskins WJ; Rubin SC; Dulaney E; Chapman D; Almadrones L; Saigo P; Markman M; Hakes T; Reichman B; Jones WB
Gynecol Oncol; 1989 Sep; 34(3):365-71. PubMed ID: 2548935
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
[TBL] [Abstract][Full Text] [Related]
26. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer.
Varia M; Rosenman J; Venkatraman S; Askin F; Fowler W; Walton L; Halle J; Currie J
Cancer; 1988 Mar; 61(5):919-27. PubMed ID: 3338057
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
29. Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer.
Franchin G; Tumolo S; Scarabelli C; De Paoli A; Boz G; Crivellari D; Arcicasa M; Bortolus R; Gobitti C; Minatel E
Gynecol Oncol; 1991 Jun; 41(3):206-11. PubMed ID: 1869096
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.
Jacob JH; Gershenson DM; Morris M; Copeland LJ; Burke TW; Wharton JT
Gynecol Oncol; 1991 Aug; 42(2):146-50. PubMed ID: 1894174
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
32. [Long-term clinical course after second laparotomy in ovarian cancer].
Stöckle E; Chauvergne J; Pigneux J; Avril A; Bussières E; Thomas L; Chevalier M; Marée D
Bull Cancer; 1990; 77(11):1087-98. PubMed ID: 2275986
[TBL] [Abstract][Full Text] [Related]
33. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
[TBL] [Abstract][Full Text] [Related]
34. [Abdominopelvic radiation therapy in the treatment of ovarian carcinoma. Study of a continuous series of 167 patients].
Thomas L; Pigneux J; Chauvergne J; Stöckle E; Bussières E; Chemin A; Toulouse C
Bull Cancer Radiother; 1994; 81(1):23-31. PubMed ID: 7893520
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
Lund B; Williamson P
Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190
[TBL] [Abstract][Full Text] [Related]
36. Consolidative 32P after second-look laparotomy for ovarian carcinoma.
Condra KS; Mendenhall WM; Morgan LS; Marcus RB
Radiat Oncol Investig; 1998; 6(2):97-102. PubMed ID: 9572686
[TBL] [Abstract][Full Text] [Related]
37. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
38. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
[TBL] [Abstract][Full Text] [Related]
39. 32P following negative second-look laparotomy for epithelial ovarian cancer.
Rogers L; Varia M; Halle J; Freddo J; Qaqish B; O'Keefe T; Fowler W
Gynecol Oncol; 1993 Aug; 50(2):141-6. PubMed ID: 8375727
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Rubin SC; Hoskins WJ; Saigo PE; Chapman D; Hakes TB; Markman M; Reichman B; Almadrones L; Lewis JL
Gynecol Oncol; 1991 Aug; 42(2):137-41. PubMed ID: 1894172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
